

# PermaWay 600 mg intramammary suspension for cattle

Authorised

- Cloxacillin hemibenzathine

## Product identification

**Medicine name:**

PermaWay 600 mg intramammary suspension for cattle

Permaway 600 mg Suspensie voor intramammair gebruik

Permaway 600 mg Suspension intramammaire

Permaway 600 mg Suspension zur intramammären Anwendung

**Active substance:**

Cloxacillin hemibenzathine

**Target species:**

Cattle (dry cow)

**Route of administration:**

Intramammary use

## Product details

**Active substance and strength:**

Cloxacillin hemibenzathine

765.40 milligram(s) / 1.00 Syringe

---

**Pharmaceutical form:**

Intramammary suspension

---

**Withdrawal period by route of administration:**

**Intramammary use:**

- 

**Cattle (dry cow)**

- Meat and offal. 28 day
- Milk. no withdrawal period

Milk: Interval between treatment and calving is 42 days or longer: 4 days after calving. Interval between treatment and calving is less than 42 days: 46 days after treatment

---

**Anatomical therapeutic chemical veterinary (ATCvet) codes:**

QJ51CF02

---

**Legal status of supply:**

Veterinary medicinal product subject to veterinary prescription

---

**Authorisation status:**

Valid

---

**Authorised in:**

Belgium

---

**Available in:**

Belgium

---

**Package description:**

box containing 96 intramammary syringes  
box containing 48 intramammary syringes  
box containing 24 intramammary syringes

---

## Additional information

**Entitlement type:**

Marketing Authorisation

---

**Legal basis of product authorisation:**

Hybrid application (Article 13(3) of Directive No 2001/82/EC)

---

**Marketing authorisation holder:**

Vetoquinol

---

**Marketing authorisation date:**

31/08/2021

---

**Manufacturing sites for batch release:**

Vetoquinol Biowet Sp. z o.o.

---

**Responsible authority:**

Federal Agency For Medicines And Health Products

---

**Authorisation number:**

BE-V589635

---

**Date of authorisation status change:**

8/10/2021

---

**Reference member state:**

Spain

---

**Procedure number:**

ES/V/0384/001

---

**Concerned member states:**

Austria Belgium Cyprus Czechia Estonia France Germany Greece Hungary  
Ireland Italy Latvia Lithuania Luxembourg Malta Netherlands Poland  
Portugal Romania Slovakia Slovenia United Kingdom (Northern Ireland)

---

To consult adverse reactions on veterinary medicinal products please go to [www.adrreports.eu/vet](http://www.adrreports.eu/vet)

## Documents

### Package Leaflet

This document does not exist in this language (English). You can find it in another language below.

### Summary of Product Characteristics

English (PDF)

Published on: 22/12/2023

[Download](#)

### Combined File of all Documents

### Labelling

This document does not exist in this language (English). You can find it in another language below.